BACKGROUND: Infusion of anti- @entity5 @entity39 factor-alpha appears to be highly effective in @entity1 with @entity30 . AIM: To assess the effect of infliximab on the quality of life in @entity1 with active or fistulizing disease, as measured by the @entity29 questionnaire, and to examine the impact on its four dimensions. METHODS: An observational study was conducted in 65 @entity1 . An infusion of 5 mg/kg infliximab was given at week 0 in @entity1 with active disease and at week 0, 2 and 6 in fistulizing disease. Changes from baseline in the total and dimensional @entity29 questionnaire scores were calculated and compared between the @entity1 groups. Potential predictors of change in the quality of life were identified. RESULTS: In the active disease group, at week 4, the mean total and dimensional @entity29 questionnaire scores improved compared to baseline (P < 0.001). In the fistulizing group, at week 6, all scores changed from baseline (P < 0.05). Improvement in the total @entity29 questionnaire score correlated well with the improvement of the @entity30 activity index. Systemic and social scores improved more than bowel and emotional scores. Inflammatory @entity30 and a young age at diagnosis were predictors for a better response to infliximab therapy. CONCLUSIONS: Infliximab therapy improves all dimensions of the quality of life in @entity1 with @entity30 .

Effects of anti- @entity5 XXXX factor-alpha therapy on the quality of life in @entity30 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour'] @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease'] @entity30 :: ('MESH:D003424', 'Disease') :: ["Crohn's disease"]
@entity39 :: (MESH:D009336,Disease) :: ['necrosis']
